Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?

Core Insights - Alnylam Pharmaceuticals (ALNY) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum [1][2] - The rising trend in estimate revisions reflects growing analyst optimism regarding the company's earnings prospects, which is expected to positively impact its stock price [2][3] Current-Quarter Estimate Revisions - The company is projected to earn $0.50 per share for the current quarter, indicating a year-over-year increase of +200.0% [6] - The Zacks Consensus Estimate for Alnylam has risen by 62.96% over the last 30 days, with four estimates increasing and no negative revisions [6] Current-Year Estimate Revisions - For the full year, Alnylam is expected to earn $1.61 per share, representing a year-over-year change of +8,150.0% [7] - The trend for current-year estimate revisions is positive, with six estimates moving higher and no negative revisions [7] Zacks Rank - Alnylam currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions that can guide investment decisions [8] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [8] Bottom Line - Investors have shown confidence in Alnylam due to solid estimate revisions, reflected in a 21.1% stock gain over the past four weeks, suggesting potential for further growth [9]